2024
Self‐reported hearing loss is associated with faster cognitive and functional decline but not diagnostic conversion in the ADNI cohort
Miller A, Sharp E, Wang S, Zhao Y, Mecca A, van Dyck C, O'Dell R, Initiative F. Self‐reported hearing loss is associated with faster cognitive and functional decline but not diagnostic conversion in the ADNI cohort. Alzheimer's & Dementia 2024 PMID: 39324520, DOI: 10.1002/alz.14252.Peer-Reviewed Original ResearchSelf-reported hearing lossFunctional Activities QuestionnaireHearing lossMild cognitive impairmentModifiable risk factorsMild cognitive impairment participantsFunctional declineImpairment diagnosisModified Preclinical Alzheimer Cognitive CompositeRate of functional declineRate of cognitive declinePreclinical Alzheimer Cognitive CompositeRisk factorsCognitive impairmentSignificant longitudinal associationsActivity QuestionnaireLongitudinal associationsAlzheimer's Disease Neuroimaging InitiativeLongitudinal relationshipCognitive compositeCN participantsIncreased riskCognitive declineParticipantsDiagnostic conversionAdverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)
Zeng L, Perin J, Gross A, Shade D, Lanctôt K, Lerner A, Mintzer J, Brawman‐Mintzer O, Padala P, van Dyck C, Porsteinsson A, Craft S, Levey A, Herrmann N, Rosenberg P. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial). International Journal Of Geriatric Psychiatry 2024, 39: e6108. PMID: 38858522, PMCID: PMC11265565, DOI: 10.1002/gps.6108.Peer-Reviewed Original ResearchConceptsMethylphenidate groupTreating apathyPlacebo-controlled trial of methylphenidateTreatment of apathyAssociated with methylphenidateEffects of methylphenidateTrial of methylphenidateAlzheimer's diseaseFollow-upNo treatment group differencesAdverse effects of methylphenidateDiastolic blood pressureSymptom ChecklistAdverse eventsTreatment group differencesMonitoring weightMethylphenidate useMethylphenidate treatmentMedical comorbiditiesPlacebo groupParticipantsMethylphenidateGroup differencesPlacebo-controlled trialMonthly visits
2023
Feasibility Study for Longitudinal Retinal Imaging in the Anti‐Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Trial
Rissman R, Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Aggarwal N, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Rafii M, Aisen P, Sperling R. Feasibility Study for Longitudinal Retinal Imaging in the Anti‐Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Trial. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079580.Peer-Reviewed Original ResearchAnti-Amyloid TreatmentAsymptomatic Alzheimer's diseaseFeasibility of retinal imagingLongitudinal Evaluation of Amyloid RiskCohort of individualsAlzheimer's diseaseResults ParticipantsAnti-amyloidA4 trialAD-diagnosed patientsRetinal spotsPositron emission tomographyStandardized uptake value ratioAmyloid positron emission tomographyLongitudinal evaluationRisk detectionClinically normal individualsParticipantsPET standardized uptake value ratioFeasibility studyClinicCross-sectionRetinal amyloid depositsAmyloid depositsIndividualsP105: Measuring clinically relevant change in apathy symptoms in ADMET 2
Tuma S, Herrmann N, Perin J, Rosenberg P, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, CraG S, Levey A, Shade D, Mintzer J, Lanctôt K. P105: Measuring clinically relevant change in apathy symptoms in ADMET 2. International Psychogeriatrics 2023, 35: 126-127. DOI: 10.1017/s1041610223002569.Peer-Reviewed Original ResearchImpression of ChangeChange scoresMeasure clinically relevant changesNPI apathy scoreEffect sizeClinical impression of changeMinimal clinically significant improvementClinical Global Impression of ChangeSpearman correlationClinical Global ImpressionClinically significant improvementSix-month visitGlobal Impression of ChangePsychosocial interventionsClinically relevant changesApathy symptomsAssessment ScaleAssessment Change ScoreMann-Whitney U testComplete dataWorsened groupParticipantsApathyNo changeTreatment trialsPrincipal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease
O'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Ni G, Chupak A, Zhao W, Salardini E, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease. NeuroImage Clinical 2023, 39: 103457. PMID: 37422964, PMCID: PMC10338149, DOI: 10.1016/j.nicl.2023.103457.Peer-Reviewed Original ResearchConceptsCognitive domainsCognitive performanceSubjects' scoresCortical regionsNeuropsychological batteryEarly Alzheimer's diseaseAD groupBilateral regionsNormal participantsNegative loadingsCognitive impairmentCN participantsAlzheimer's diseaseParticipantsStructural correlatesStrong contributionParticipant characteristicsScoresPositive loadingsData-driven approachTotal variancePrincipal component analysisSpecific spatial patternsCorrelation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial
Lanctôt K, Sankhe K, Perin J, Herrmann N, Brawman-Mintzer O, Lerner A, Mintzer J, Padala P, Rosenberg P, Shade D, van Dyck C, Porsteinsson A. Correlation between changes in apathy and global cognition in apathetic associated with Alzheimer's disease: analysis of the Apathy Dementia Methylphenidate 2 (ADMET 2) clinical trial. American Journal Of Geriatric Psychiatry 2023, 31: s100-s101. DOI: 10.1016/j.jagp.2022.12.146.Peer-Reviewed Original ResearchDigit Span BackwardMini-Mental Status ExaminationSelective attentionGlobal cognitionApathy scoresGreater cognitive declineExecutive functionDigit spanCognitive testsCognitionMethylphenidate groupApathy symptomsCognitive declineSignificant apathyMethylphenidateCognitive impairmentStatus ExaminationApathy subscaleMemoryChange scoresApathyDisease dementiaAlzheimer's disease dementiaParticipantsAttention
2020
Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau
Digma L, Madsen J, Rissman R, Jacobs D, Brewer J, Banks S, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Shaw L, Liu E, Montine T, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Jiminez G, Harvey D, Donohue M, Bernstein M, Fox N, Thompson P, Schuff N, DeCArli C, Borowski B, Gunter J, Senjem M, Vemuri P, Jones D, Kantarci K, Ward C, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Landau S, Cairns N, Householder E, Reinwald L, Lee V, Korecka M, Figurski M, Crawford K, Neu S, Foroud T, Potkin S, Shen L, Kelley F, Kim S, Nho K, Kachaturian Z, Frank R, Snyder P, Molchan S, Kaye J, Quinn J, Lind B, Carter R, Dolen S, Schneider L, Pawluczyk S, Beccera M, Teodoro L, Spann B, Brewer J, Vanderswag H, Fleisher A, Heidebrink J, Lord J, Petersen R, Mason S, Albers C, Knopman D, Johnson K, Doody R, Meyer J, Chowdhury M, Rountree S, Dang M, Stern Y, Honig L, Bell K, Ances B, Morris J, Carroll M, Leon S, Householder E, Mintun M, Schneider S, Oliver A, Griffith R, Clark D, Geldmacher D, Brockington J, Roberson E, Grossman H, Mitsis E, deToledo-Morrell L, Shah R, Duara R, Varon D, Greig M, Roberts P, Albert M, Onyike C, D’Agostino D, Kielb S, Galvin J, Pogorelec D, Cerbone B, Michel C, Rusinek H, de Leon M, Glodzik L, De Santi S, Doraiswamy P, Petrella J, Wong T, Arnold S, Karlawish J, Wolk D, Smith C, Jicha G, Hardy P, Sinha P, Oates E, Conrad G, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Mulnard R, Thai G, Mc Adams Ortiz C, Womack K, Mathews D, Quiceno M, Arrastia R, King R, Weiner M, Cook K, DeVous M, Levey A, Lah J, Cellar J, Burns J, Anderson H, Swerdlow R, Apostolova L, Tingus K, Woo E, Silverman D, Lu P, Bartzokis G, Radford N, Parfitt F, Kendall T, Johnson H, Farlow M, Hake A, Matthews B, Herring S, Hunt C, van Dyck C, Carson R, MacAvoy M, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung G, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam M, Lipowski K, Wu C, Johnson N, Sadowsky C, Martinez W, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Frey M, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Sirrel S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Allard J, Lerner A, Ogrocki P, Hudson L, Fletcher E, Carmichael O, Olichney J, DeCarli C, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Adeli A, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Santulli R, Kitzmiller T, Schwartz E, Sink K, Williamson J, Garg P, Watkins F, Ott B, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Mintzer J, Spicer K, Bachman D, Finger E, Pasternak S, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Ponto L, Shim H, Smith K, Relkin N, Chaing G, Raudin L, Smith A, Fargher K, Raj B. Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. Brain Communications 2020, 2: fcaa025. PMID: 32337508, PMCID: PMC7166251, DOI: 10.1093/braincomms/fcaa025.Peer-Reviewed Original ResearchMemory scoresMemory reserveRey Auditory Verbal Learning TestRey Auditory Verbal Learning Test scoreAuditory Verbal Learning TestLogical memory performanceVerbal memory abilitiesVerbal Learning TestVerbal memory impairmentVerbal memory scoresLogical Memory scoresNational Alzheimer's Coordinating Center participantsLearning TestMemory performanceAlzheimer's Disease Neuroimaging Initiative participantsMemory abilityMore tauMemory impairmentTest scoresSex differencesC3 scoresCenter sampleCenter participantsParticipantsHigh reserves